Phase III study of low-dose intravenous OKT3 and subcutaneous interleukin-2 in metastatic cancer
- 31 December 1993
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 29 (15) , 2108-2113
- https://doi.org/10.1016/0959-8049(93)90044-g
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patientsCancer Immunology, Immunotherapy, 1993
- ACTIVATION OF HUMAN T CELLS IN VIVO FOLLOWING TREATMENT OF TRANSPLANT RECIPIENTS WITH OKT3Transplantation, 1990
- Neurotoxicity after Treatment with Muromonab-CD3New England Journal of Medicine, 1990
- Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignanciesThe Lancet, 1990
- Systemic Reaction to the Anti–T-Cell Monoclonal Antibody OKT3 in Relation to Serum Levels of Tumor Necrosis Factor and Interferon-αNew England Journal of Medicine, 1989
- RELEASE OF TUMOR NECROSIS FACTOR, INTERLEUKIN-2, AND GAMMA-INTERFERON IN SERUM AFTER INJECTION OF OKT3 MONOCLONAL ANTIBODY IN KIDNEY TRANSPLANT RECIPIENTSTransplantation, 1989
- In Vivo Administration of Anti-CD3 Prevents Malignant Progressor Tumor GrowthScience, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadaveric Renal TransplantsNew England Journal of Medicine, 1985